Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Connect Biopharma Holdings Ltd

Company price
0.6772 USD 0.01 ( 1.79%)
Last update at 2026-11-13T21:28:00Z
VOLUME
233684
Market Cap
73.68M

Momentum Score

…

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.64
Low
0.70
High
52 Week Price Range
1.06
Low
3.82
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Connect Biopharma Holdings is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for immune-mediated and inflammatory diseases. Its long-term growth drivers include advancement of its clinical-stage pipeline, potential strategic partnerships, and regulatory approvals in targeted indications that may benefit patients with unmet needs. Investors may find the company attractive because successful trial readouts could materially de-risk programs and support commercial opportunities.

The primary investment risks are program-level clinical and regulatory failure combined with limited operating history and the likely need for additional financing to complete development and commercialization.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.67
Dividend Yield
-
Revenue TTM
2.95M
Revenue Per Share
0.05
Gross Profit TTM
2.95M
Debt / Equity
0.02
ROE
-140.51%
Net Debt
-37.66M
ROCE
-136.77%
Diluted EPS TTM
-0.80

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -55.28M -15.40M -61.99M -795.02M -1305.13M
Net income -55.48M -15.63M -62.11M -797.05M -1306.82M
Selling general administrative 20.34M 19.23M 16.05M 139.44M 122.44M
Selling and marketing expenses - - 13.51M - -
Gross profit 0.06M 26.03M -0.99M - -
Reconciled depreciation 0.70M 0.66M 0.99M 6.94M 4.08M
Ebit -58.07M -22.45M -69.06M -805.59M -631.44M
Ebitda -57.37M -21.79M -68.34M -762.07M -1305.08M
Depreciation and amortization 0.70M 0.66M 0.72M 43.52M -673.65M
Operating income -58.07M -22.45M -69.06M -805.59M -631.44M
Other operating expenses 58.14M 48.48M 69.06M 785.22M 621.47M
Interest expense - - 0.02M 0.14M 0.04M
Tax provision 0.20M 0.22M 0.12M 2.04M 1.70M
Interest income 2.27M 4.45M 2.71M 10.71M 0.62M
Net interest income 2.27M 4.45M 2.69M 10.57M 0.58M
Income tax expense 0.20M 0.22M 0.12M 2.04M 1.70M
Total revenue 0.06M 26.03M 0.00M 0.00M 0.00M
Total operating expenses 58.14M 48.48M 69.06M 785.22M 621.47M
Cost of revenue - 0.66M 0.99M - -
Total other income expense net 2.79M 7.05M 7.07M 10.57M -673.69M
Net income from continuing ops -55.48M -15.63M -59.50M -797.05M -1306.82M
Net income applicable to common shares - - - - -1306.82M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 56.08M 101.28M 125.89M 1211.93M 1855.66M
Intangible assets 0.04M 0.05M 0.06M 22.04M 22.55M
Other current assets 6.43M 2.20M - - 3.95M
Total liab 14.10M 9.12M 24.85M 115.06M 119.83M
Total stockholder equity 41.98M 92.17M 101.04M -3175.22M 1735.83M
Other current liab 11.16M 7.80M 3.00M 24.39M 32.84M
Common stock 0.01M 0.01M 0.01M 0.07M 0.07M
Capital stock 0.01M 0.01M 0.01M 0.07M 0.07M
Retained earnings -400.83M -345.36M -539.35M -3175.22M -2378.16M
Other liab - - - - 5.00M
Good will - - - - -21.99M
Other assets - - - - 18.81M
Cash 38.34M 78.23M 106.01M 550.27M 1706.88M
Total current liabilities 13.61M 8.46M 24.26M 108.82M 114.67M
Current deferred revenue 0.17M 0.16M 13.32M - -
Net debt -37.66M -78.05M -105.54M -547.28M -1706.09M
Short term debt 0.32M 0.15M 0.28M 1.29M 0.63M
Short long term debt total 0.69M 0.18M 0.47M 3.00M 0.79M
Other stockholder equity 444.00M 439.18M 648.26M -71.19M 4155.17M
Property plant equipment - - - - 82.16M
Total current assets 50.93M 96.96M 120.97M 1084.94M 1754.13M
Long term investments - - 0.00M 65.74M -
Net tangible assets - - - - 1735.27M
Short term investments 6.00M 15.48M 12.65M 511.25M 0.00M
Net receivables 0.16M 1.05M 0.18M 1.61M 47.26M
Accounts payable 1.96M 0.34M 7.66M 83.14M 81.19M
Accumulated other comprehensive income -1.19M -1.67M -7.88M 71.12M -41.24M
Non currrent assets other 0.65M 0.03M 0.13M 0.24M 18.81M
Non current assets total 5.15M 4.32M 4.92M 126.99M 101.52M
Capital lease obligations 0.69M 0.18M 0.47M 3.00M 0.79M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 10.25M -3.45M 75.16M -571.31M 13.50M
Change to liabilities - - - - 56.60M
Total cashflows from investing activities 9.82M -3.45M 75.16M - -34.02M
Net borrowings - - -0.29M - -0.81M
Total cash from financing activities 1.09M 0.23M -0.25M -0.62M 1316.10M
Change to operating activities - - - - -19.66M
Net income -55.48M -15.63M -59.38M -795.02M -1305.13M
Change in cash -39.89M -27.43M 27.00M -1156.61M 696.80M
Begin period cash flow 78.23M 105.66M 79.01M 1706.88M 1010.08M
End period cash flow 38.34M 78.23M 106.01M 550.27M 1706.88M
Total cash from operating activities -51.21M -23.61M -47.93M -679.66M -544.93M
Issuance of capital stock - - 0.04M 0.13M 1431.78M
Depreciation 0.70M 0.66M 0.99M 6.94M 4.08M
Other cashflows from investing activities 0.78M 0.12M -0.08M - -22.28M
Dividends paid - - - - 0.24M
Change to account receivables 0.78M -0.79M 1.04M - -16.12M
Sale purchase of stock - - 0.00M 0.00M -3.67M
Other cashflows from financing activities 1.09M 0.23M 75.16M 0.76M -110.95M
Change to netincome - - - - 737.00M
Capital expenditures 0.43M 0.75M 0.29M 29.32M 47.53M
Change in working capital 0.58M -15.49M 9.48M 49.02M 20.82M
Stock based compensation 3.73M 6.73M 3.26M 45.60M 57.86M
Other non cash items -0.74M 0.12M -2.28M -9.25M 0.04M
Free cash flow -51.64M -24.36M -48.22M -708.99M -592.46M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CNTB
Connect Biopharma Holdings Ltd
0.01
1.79%
0.68 - 0.77 24.95 4.04 26.33 0.19
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Connect Biopharma Holdings Ltd

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

3580 Carmel Mountain Road, San Diego, CA, United States, 92130

877 245 2787

64

Name Title Year Born
Dr. Wubin Pan M.B.A., Ph.D. Co-Founder, Pres & Chairman of Directors 1965
Dr. Zheng Wei Ph.D. Co-Founder, CEO & Director 1964
Mr. Steven Chan Chief Financial Officer 1972
Mr. Jiang Bian J.D. Gen. Counsel & Chief Compliance Officer NA
Dr. Lei Sun Ph.D. VP of Biologics & Head of CMC 1964
Dr. Raul Collazo Ph.D. VP & Global Head of Medical Affairs NA
Dr. Malinda V. Longphre Ph.D. Head of US Clinical Operations NA
Dr. Chin Lee M.D., M.P.H. Chief Medical Officer 1970
Dr. Wubin Pan M.B.A., Ph.D. Co-Founder, President & Chairman of the Board of Directors 1965
Mr. Jiang Bian J.D. General Counsel & Chief Compliance Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…